Aminoglycosides are commonly used to treat infections in CF patients and are highly ototoxic. The incidence of tobramycin-induced hearing loss, tinnitus, vertigo or dizziness (ototoxicity) varies widely from 0 to 56% secondary to variation in patient enrollment, dosing, audiometry, and ototoxic criteria. The aim of this study is to determine the incidence of ototoxicity after one course of once-daily IV tobramycin in CF patients. Adult CF patients with acute pulmonary exacerbations were enrolled on IV tobramycin (10 mg/kg/d, ≥10 days). Pure-tone audiometry was performed for standard and extended high frequencies in the sensitive range for ototoxicity (SRO). American-Speech-Language-Hearing-Association cochleotoxicity criteria were applied. Distortion product otoacoustic emissions (DPOAE) and the words-in-noise-test (WINT) were assessed. Tinnitus Functional Index (TFI) and Vertigo Symptoms Scale (VSS) were used. Eighteen CF patients, mean age 31.1 (18-59), were enrolled. The incidence of cochleotoxic change from baseline at 2 and 4 weeks post-treatment was 89% and 93%. For DPOAE, a measure of outer hair-cell function, the incidence of ≥5 dB decrease was 82% and 80%. For WINT, a measure of word recognition, the incidence of ≥10% decrease was 17% and 40%. For TFI, the incidence of ≥10pt increase was 12% and 8%, and for VSS, the incidence of ≥6pt increase was 0% and 8%. One course of IV tobramycin was sufficient to cause hearing loss and other ototoxic symptoms four weeks after treatment ended. Audiometric measures were more sensitive to ototoxic change than TFI & VSS. Age and duration of tobramycin treatment were not obvious factors for predicting ototoxicity.

中文翻译：

---

接受静脉妥布霉素治疗急性肺恶化的囊性纤维化患者的耳毒性

氨基糖苷类药物常用于治疗 CF 患者的感染，并且具有高度的耳毒性。妥布霉素引起的听力损失、耳鸣、眩晕或头晕（耳毒性）的发生率在 0 至 56% 之间变化很大，这是由于患者登记、剂量、听力测定和耳毒性标准的变化所致。本研究的目的是确定 CF 患者每天一次静脉注射妥布霉素一个疗程后耳毒性的发生率。患有急性肺部恶化的成年 CF 患者被纳入 IV 妥布霉素（10 mg/kg/d，≥10 天）。对耳毒性 (SRO) 敏感范围内的标准和扩展高频进行纯音测听。应用了美国语言听力协会耳蜗毒性标准。对失真产物耳声发射 (DPOAE) 和噪声测试 (WINT) 进行了评估。使用耳鸣功能指数（TFI）和眩晕症状量表（VSS）。招募了 18 名 CF 患者，平均年龄 31.1 (18-59)。治疗后 2 周和 4 周时耳蜗毒性变化的发生率分别为 89% 和 93%。对于 DPOAE（一种外毛细胞功能的量度），≥5 dB 降低的发生率分别为 82% 和 80%。对于 WINT（一种单词识别量度），≥10% 下降的发生率分别为 17% 和 40%。对于 TFI，≥10pt 增加的发生率为 12% 和 8%，对于 VSS，≥6pt 增加的发生率为 0% 和 8%。治疗结束 4 周后，一个疗程的 IV 妥布霉素足以引起听力损失和其他耳毒性症状。听力测量比 TFI 和 VSS 对耳毒性变化更敏感。年龄和妥布霉素治疗时间不是预测耳毒性的明显因素。